生物药物在异性肺部疾病中的使用:争议和共识
Luis Pérez de Llano1, David Dacal Rivas2, Ian Pavord3
1Pneumology Service, Lucus Augusti University Hospital, EOXI Lugo, Monforte, Cervo, Lugo, Spain.
概括
生物药物为治疗由eosinophilic炎症驱动的肺部疾病提供了口服皮质类固醇的有希望的替代品. 这篇评论探讨了它们在慢性埃索诺菲尔性肺炎和过敏支气管肺炎阿斯伯吉洛症等疾病中的应用.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乙酸性炎症驱动着几种肺部疾病.
- 目前的治疗方法,如口服皮质类固醇 (OCS),具有显著的毒性.
- 生物药物已经在管理eosinophilic疾病方面取得了成功.
研究的目的:
- 审查关于使用生物药物治疗异性肺部疾病的文献.
- 探索OCS的替代方案,以治疗慢性乙酸性肺炎,过敏性支气管肺炎 (ABPA) 和高乙酸性综合征.
主要方法:
- 关于生物药物治疗eosinophilic肺部疾病的研究文献综述.
- 专注于急性和慢性乙酸性肺炎,ABPA和高乙酸性综合征.
主要成果:
- 生物药物代表了对eosinophilic肺部疾病的潜在治疗策略.
- 利用对病理生理学的理解是实施生物疗法的关键.
结论:
- 生物药物提供了有价值的治疗选择,用于管理eosinophilic肺部疾病.
- 由于OCS的毒性,减少对OCS的依赖至关重要.
- 对生物应用的进一步研究是有必要的.
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
1.3K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.3K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.1K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.1K
Asthma-IV: Diagnostic and Management
3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
Asthma: Pathogenesis and Management
1.5K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
Antiasthma Drugs: Leukotriene Modifiers
2.1K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.1K
COPD: Management Using Bronchodilators and Corticosteroids
1000
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1000


